Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + salazosulfapyridine
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
Etanercept + salazosulfapyridine is a combination therapy used primarily in the management of rheumatoid arthritis, especially in patients who are intolerant to methotrexate. Etanercept is a biologic agent that acts as a tumor necrosis factor (TNF) inhibitor, blocking the activity of TNF-alpha, a cytokine involved in systemic inflammation. Salazosulfapyridine (also known as sulfasalazine) is a conventional disease-modifying antirheumatic drug (DMARD) with anti-inflammatory and immunomodulatory properties; it works by inhibiting various inflammatory mediators and modulating immune responses. The combination aims to enhance therapeutic efficacy for rheumatoid arthritis while providing an alternative for patients unable to tolerate methotrexate[1][4]. Clinical studies suggest this combination can be effective and well-tolerated in such populations[1][4].
- Other names
- etanercept + sulfasalazine
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on etanercept + salazosulfapyridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + salazosulfapyridine.